Tuesday, 14 April 2020

SMS Pharma provides updates against USFDA statement in connection with Ranitidine

In September 2019, The USFDA has observed that, some ranitidine medicines contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. SMS Pharma is one of the manufacturer of Ranitidine HCl Active Pharmaceuticals Ingredient (API).



source https://www.pharmatutor.org/pharma-news/2020/sms-pharma-provides-updates-against-usfda-statement-in-connection-with-ranitidine
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Pharmaceutical Industry and pharma / Life Sciences institute openings 2025

  Intas Pharma Walk in Drive for M.Pharm, B.Pharm | Multiple Posts M.Pharma / B.Pharma. Injectable/Parenteral/Sterile - Aseptic, Manufacturi...